Article Text

Download PDFPDF
Increased serum nesfatin-1 levels in patients with inflammatory bowel diseases
  1. Şengül Beyaz1,
  2. Erdem Akbal2
  1. 1Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey
  2. 2Department of Gastroenterology Advanced Endoscopy Unit, Memorial Bahçelievler Hospital, Istanbul, Turkey
  1. Correspondence to Dr Şengül Beyaz, Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul 34093, Turkey; sengulbeyaz{at}gmail.com

Abstract

Background Adipokines are adipose tissue–derived secreted molecules that can exert anti-inflammatory or proinflammatory activities. Altered expression of adipokines has been described in various inflammatory diseases, including inflammatory bowel diseases (IBDs) such as Crohn’s disease (CD) and ulcerative colitis (UC). Little is known about nesfatin-1, a recently identified adipokine, in IBD. The aim of this study was to investigate serum nesfatin-1 levels in patients with IBD.

Methods This study included a total of 52 adult individuals (17 patients with CD, 18 patients with UC and 17 healthy volunteers) with similar age and body mass index. Serum nesfatin-1 levels were measured by ELISA in healthy individuals and patients with IBD in their active and remission periods. Blood inflammation markers including C reactive protein (CRP), erythrocyte sedimentation (ESR) and white cell count (WCC) were also measured in patients.

Results We found significantly elevated levels of serum nesfatin-1 in the active disease period in both patients with CD (p=0.00003) and patients with UC (p=0.00001), compared with healthy individuals. Serum nesfatin-1 levels moderately decreased in the remission period; however, they were still significantly higher than that of healthy individuals. Receiver operating characteristic curve analyses indicated serum nesfatin-1 with an excellent diagnostic value for IBD. Finally, patients had significantly high CRP, ESR and WCC in the active IBD; however, we found the nesfatin-1 strongly correlated only with ESR in the active CD.

Conclusion This is the first study investigating the circulating levels of nesfatin-1 in patients with IBD. Serum nesfatin-1 may serve as an additional inflammatory marker for diagnosis of IBD in affected individuals.

  • inflammatory bowel disease
  • gastroenterology
  • adult gastroenterology

Statistics from Altmetric.com

Footnotes

  • Contributors SB has made substantial contributions to conception and design, and acquisition of data, and analysis and interpretation of data; has been involved in drafting the manuscript and revising it critically, gave final approval of the version to be published and agrees to be accountable for all aspects of the work related to its accuracy or integrity. EA has made substantial contributions to conception and design, and acquisition of data, and analysis and interpretation of data; has been involved in drafting the manuscript and revising it critically, gave final approval of the version to be published and agrees to be accountable for all aspects of the work related to its accuracy or integrity.

  • Funding This study was supported by Çanakkale Onsekiz Mart University Scientific Research Projects Commission with project number 432.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.